Ogawa C, Tsuchiya K, Tomosugi N, Maeda K
Int J Mol Sci. 2024; 25(3).
PMID: 38338786
PMC: 10855056.
DOI: 10.3390/ijms25031508.
Zhang L, Gan L, Li K, Xie P, Tan Y, Wei G
Eur J Clin Pharmacol. 2022; 78(9):1421-1434.
PMID: 35711066
PMC: 9365747.
DOI: 10.1007/s00228-022-03328-9.
Zuo Q, Wang T, Zhu L, Li X, Luo Q
Ren Fail. 2022; 44(1):94-102.
PMID: 35156909
PMC: 8856040.
DOI: 10.1080/0886022X.2021.2021237.
Lorentz C, Tucker E, Verbout N, Shatzel J, Olson S, Markway B
Blood. 2021; 138(22):2173-2184.
PMID: 34086880
PMC: 8641100.
DOI: 10.1182/blood.2021011725.
Nguyen L, Meaney C, Rao G, Panesar M, Krzyzanski W
AAPS J. 2020; 22(2):40.
PMID: 32016602
DOI: 10.1208/s12248-020-0424-9.
Testing two (of several) intravenous iron dosing strategies in hemodialysis.
Yu M, Chertow G
Ann Transl Med. 2019; 7(Suppl 3):S129.
PMID: 31576336
PMC: 6685907.
DOI: 10.21037/atm.2019.05.75.
Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations.
Rostoker G, Vaziri N
Heliyon. 2019; 5(7):e02045.
PMID: 31338466
PMC: 6627982.
DOI: 10.1016/j.heliyon.2019.e02045.
Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
OLone E, Hodson E, Nistor I, Bolignano D, Webster A, Craig J
Cochrane Database Syst Rev. 2019; 2:CD007857.
PMID: 30790278
PMC: 6384096.
DOI: 10.1002/14651858.CD007857.pub3.
Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T
PLoS One. 2017; 12(6):e0179608.
PMID: 28662118
PMC: 5491034.
DOI: 10.1371/journal.pone.0179608.
Markers of iron status in chronic kidney disease.
Gaweda A
Hemodial Int. 2017; 21 Suppl 1:S21-S27.
PMID: 28328097
PMC: 6247786.
DOI: 10.1111/hdi.12556.
Comparative Effectiveness of Dialyzers: A Longitudinal, Propensity Score-Matched Study of Incident Hemodialysis Patients.
Sibbel S, Hunt A, Laplante S, Beck W, Gellens M, Brunelli S
ASAIO J. 2016; 62(5):613-22.
PMID: 27442860
PMC: 5010276.
DOI: 10.1097/MAT.0000000000000409.
Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.
Rostoker G, Vaziri N, Fishbane S
Drugs. 2016; 76(7):741-57.
PMID: 27091216
PMC: 4848337.
DOI: 10.1007/s40265-016-0569-0.
Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
Fishbane S, Singh A, Cournoyer S, Jindal K, Fanti P, Guss C
Nephrol Dial Transplant. 2015; 30(12):2019-26.
PMID: 26175145
PMC: 4656038.
DOI: 10.1093/ndt/gfv277.
Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.
Gupta A, Lin V, Guss C, Pratt R, Ikizler T, Besarab A
Kidney Int. 2015; 88(5):1187-94.
PMID: 26154926
PMC: 4653585.
DOI: 10.1038/ki.2015.203.
Anaemia in kidney disease: harnessing hypoxia responses for therapy.
Koury M, Haase V
Nat Rev Nephrol. 2015; 11(7):394-410.
PMID: 26055355
PMC: 4497972.
DOI: 10.1038/nrneph.2015.82.
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.
Umanath K, Jalal D, Greco B, Umeukeje E, Reisin E, Manley J
J Am Soc Nephrol. 2015; 26(10):2578-87.
PMID: 25736045
PMC: 4587699.
DOI: 10.1681/ASN.2014080842.
Intravenous iron exposure and mortality in patients on hemodialysis.
Miskulin D, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer K
Clin J Am Soc Nephrol. 2014; 9(11):1930-9.
PMID: 25318751
PMC: 4220761.
DOI: 10.2215/CJN.03370414.
Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
Lewis J, Sika M, Koury M, Chuang P, Schulman G, Smith M
J Am Soc Nephrol. 2014; 26(2):493-503.
PMID: 25060056
PMC: 4310662.
DOI: 10.1681/ASN.2014020212.
Chapter 2: Use of iron to treat anemia in CKD.
Kidney Int Suppl (2011). 2014; 2(4):292-298.
PMID: 25018949
PMC: 4089602.
DOI: 10.1038/kisup.2012.34.
Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
Cappell K, Shreay S, Cao Z, Varker H, Paoli C, Gitlin M
BMC Nephrol. 2014; 15:116.
PMID: 25015348
PMC: 4112651.
DOI: 10.1186/1471-2369-15-116.